$123 Million is the total value of Clarus Ventures, LLC's 5 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NSTG | Nanostring Technologies Inc. | $63,985,000 | -2.3% | 3,959,440 | 0.0% | 52.08% | -13.5% | |
| SIEN | Sientra Inc. | $42,054,000 | +58.4% | 2,730,765 | 0.0% | 34.23% | +40.3% | |
| VBIV | VBI Vaccines Inc. | $10,360,000 | -11.5% | 2,691,042 | 0.0% | 8.43% | -21.6% | |
| CATB | Catabasis Pharmaceuticals Inc. | $5,835,000 | +50.3% | 2,752,488 | 0.0% | 4.75% | +33.1% | |
| ESSA Pharma Inc. | $615,000 | -47.3% | 2,121,212 | 0.0% | 0.50% | -53.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Nanostring Technologies Inc. | 20 | Q3 2018 | 60.2% |
| Sientra Inc. | 16 | Q3 2018 | 38.2% |
| Oxford Immunotex Global PLC | 14 | Q1 2017 | 17.4% |
| Catabasis Pharmaceuticals Inc. | 14 | Q3 2018 | 15.3% |
| VBI Vaccines Inc. | 10 | Q3 2018 | 11.4% |
| TetraLogic Pharmaceuticals Corporation | 9 | Q4 2015 | 12.5% |
| ESSA Pharma Inc. | 9 | Q1 2018 | 6.5% |
| Aerie Pharmaceuticals Inc. | 7 | Q4 2015 | 30.5% |
| VBI Vaccines Inc. | 7 | Q1 2016 | 9.1% |
| Ophthotech Corp | 6 | Q1 2015 | 31.5% |
View Clarus Ventures, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-15 |
| 13F-NT | 2024-02-14 |
| 13F-NT | 2023-11-14 |
| 13F-NT | 2023-08-14 |
| 13F-NT | 2023-05-15 |
| 13F-NT | 2023-02-14 |
| 13F-NT | 2022-11-14 |
| 13F-NT | 2022-08-15 |
| 13F-NT | 2022-05-16 |
| 13F-NT | 2022-02-14 |
View Clarus Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.